The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

Trial Profile

The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Maraviroc (Primary) ; Boceprevir
  • Indications Hepatitis C; HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 May 2013 Planned end date changed from 1 Sep 2012 to 1 Feb 2014 as reported by ClinicalTrials.gov record.
    • 03 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top